152 related articles for article (PubMed ID: 37142953)
1. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
3. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
4. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
7. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
9. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38459188
[TBL] [Abstract][Full Text] [Related]
10. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Li JR; Yang CR; Cheng CL; Ho HC; Chiu KY; Su CK; Chen WM; Wang SS; Chen CS; Yang CK; Ou YC
Support Care Cancer; 2013 Mar; 21(3):907-11. PubMed ID: 23262811
[TBL] [Abstract][Full Text] [Related]
12. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract][Full Text] [Related]
13. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Shou L; Chen J; Shao T; Zhang Y; Zhao S; Chen S; Shu Q
Support Care Cancer; 2023 Jun; 31(7):375. PubMed ID: 37273007
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S; Yamada T; Nakamura M; Enomoto M; Sugimoto K; Yokomizo H; Kosugi C; Ohta R; Ishimaru K; Sonoda H; Ishibashi K; Kuramochi H; Yoshida Y; Ichikawa D; Hirata K; Yoshida H; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Int J Clin Oncol; 2022 Aug; 27(8):1300-1308. PubMed ID: 35635652
[TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
